About US
Contact us
-
US FDA cracks down on importation of unapproved new drugs for personal useUS FDA cracks down on importation of unapproved new drugs for personal use The United States Food and Drug Administration (“FDA”) is cracking down on the importation of unapproved new drugs with r2010/10/28
-
Pharmacopeias of US and Kazakhstan sign accordPharmacopeias of US and Kazakhstan sign accord With the mutual goal of improving the quality of pharmaceuticals worldwide, the United States Pharmacopeial Convention (USP) and the Republican State2010/10/27
-
PAREXEL's white paper provides data on biopharmaceutical, medical device product developmentPAREXEL's white paper provides data on biopharmaceutical, medical device product development PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life s2010/10/27
-
Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglyceridesEssentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides Essentialis, Inc. announced today that the company has reached agreement with the U.S. F2010/10/26
-
Biopharmaceutical Contract Manufacturing Market: Outsourcing – What Services are Biomanufacturing Directors Looking for from CMOs?Biopharmaceutical Contract Manufacturing Market: Outsourcing – What Services are Biomanufacturing Directors Looking for from CMOs? Biopharm William Downey MBA, President HighTech Business Decisio2010/10/26
-
Evolutionary Thinking: Pfizer Continues to Set a New Pace for Drug DevelopmentEvolutionary Thinking: Pfizer Continues to Set a New Pace for Drug Development Drug Development Chris J. Hilton, M.Sc., B.Sc. Interim Head of Development Operations Pfizer, Inc. Pfizer’s Worldwide2010/10/25
-
FDA announces new label for HIV antiviral drug InviraseFDA announces new label for HIV antiviral drug Invirase The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Inv2010/10/25
-
FDA issues complete response letter for BYDUREON NDAFDA issues complete response letter for BYDUREON NDA Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S.2010/10/22
-
Mylan receives final FDA approval for Pramipexole Dihydrochloride TabletsMylan receives final FDA approval for Pramipexole Dihydrochloride Tablets Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from t2010/10/22
-
The Third Party Inspection Institution for Drug，APLs and ExcipientsPhexcom can provide one-stop inspection service for drug,APIs and excipients. For more info,please contact：info@ phexcom.com2010/10/21